GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for osteoporosis, gout and osteomalacia vs. a matched control group, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results